Earlier this month, Planet Labs PBC announced a multi-year, low nine‑figure agreement with the Swedish Armed Forces for sovereign satellites, high‑resolution data access, and space‑based awareness ...

In November 2024, Boltz-1 debuted as a fully commercially available AI model to achieve AlphaFold 3-level accuracy in predicting the 3D structure of biomolecular complexes. Since that time, the ...

The S&P 500 industrials sector has delivered a robust performance in 2025, with a year to date performance of up +18%. The sector ranked as the third-best-performing sector year to date and, outpacing ...

LOS ANGELES--(BUSINESS WIRE)--Rarity PBC, a Public Benefit Corporation dedicated to expanding the availability of transformative gene therapies for rare diseases, today announced the closing of a $4.6 ...

BERLIN — A novel investigational ileal bile acid transporter (IBAT) inhibitor, linerixibat, significantly and rapidly reduced cholestatic pruritus in patients with primary biliary cholangitis (PBC), ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of two per 100,000 people per year and an estimated prevalence of 15 per ...

Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.

Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) from the US market. The decision follows a request from the FDA.

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary cholangitis (PBC). The pharma—which earned the FDA’s accelerated approval for PBC ...

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the autoimmune disease are anti-mitochondrial antibodies (AMA), present in approximately ...